| Literature DB >> 28352322 |
Xiao-Xiang Zhai1, Ji-Cun Ding2, Zhi-Ming Tang1, Jing-Guo Li1, Xiang-Hui Chen1, Cui-Xia Zhang1.
Abstract
We evaluated the effect of Wubeizi (WBZ) ointment on keloids. Keloid-derived fibroblast primary cultures were used to evaluate the effect of the different concentration of WBZ ointment on the expression of type I and III procollagen in keloid fibroblast primary cultures using dot blot assay. Type I and II precollagen cDNA probes labeled with non-radioactive digoxin were used for dot blot. Cell cultures were divided into 4 groups: The large dose group received 1 g/ml of WBZ, middle dose, and small dose groups received 0.5 and 0.25 g/ml of WBZ, respectively. The control group received serum-free medium without WBZ. Our results showed that type I and III procollagen mRNA expression was reduced significantly in the large dose and middle dose groups compared to the control group. Type I and III procollagen mRNA expression level in the small dose group had no statistically significant difference with the control group. However, the difference between the large dose group and the small dose group was statistically significant. We concluded that WBZ ointment aqueous solution restricted keloid fibroblast proliferation by downregulating the expression of type I and III procollagen and therefore reducing collagen deposition in keloid tissue.Entities:
Keywords: Wubeizi ointment; fibroblasts; keloid; procollagen gene; proliferation
Year: 2016 PMID: 28352322 PMCID: PMC5348681 DOI: 10.3892/etm.2016.4017
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.RNA denaturing agarose gel electrophoresis. No degradation was detected in 28S and 18S bands.
Figure 2.Dot-blot results with computer gray scale scanning.
Gray value of dot blot hybridization (mean ± SD).
| Groups | n | Type I gray value | Type III gray value |
|---|---|---|---|
| Control | 6 | 204.33±4.50 | 197.67±7.55 |
| Small dose | 6 | 190.33±10.17 | 187.33±11.43 |
| Middle dose | 6 | 178.17±16.47[ | 169.17±7.08[ |
| Large dose | 6 | 171.67±7.61[ | 163.83±7.47[ |
Type I gray value F=32.15, P=0.000<0.01, type III gray value F=58.52, P=0.000<0.0001
P<0.01 comparison with the control group
P<0.05
P<0.01 comparison with the small dose group.
Figure 3.Histogram of gray value scanned of dot blot hybridization.